Cheng AY, Fantus IG: Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005, 172:213–226.
Tontonoz P, Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289–312.
Lecka-Czernik B: PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep 2010, 8:84–90.
• Lecka-Czernik B: Bone as a target of type 2 diabetes treatment. Curr Opin Investig Drugs 2009, 10:1085–1090. This article reviews the effect of T2DM and different antidiabetic therapies on the human skeleton.
Janghorbani M, Van Dam RM, Willett WC, Hu FB: Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007, 166:495–505.
Yamamoto M, Yamaguchi T, Yamauchi M, et al.: Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 2009, 24:702–709.
Vestergaard P, Rejnmark L, Mosekilde L: Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009, 84:45–55.
Schwartz AV, Hillier TA, Sellmeyer DE, et al.: Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002, 25:1749–1754.
Melton LJ, Leibson CL, Achenbach SJ, et al.: Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 2008, 23:1334–1342.
Krakauer JC, McKenna MJ, Buderer NF, et al.: Bone loss and bone turnover in diabetes. Diabetes 1995, 44:775–782.
Huang S, Kaw M, Harris MT, et al.: Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1. Bone 2010, 46:1138–1145.
Yamamoto M, Yamaguchi T, Yamauchi M, et al.: Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:1013–1019.
Vashishth D: Collagen glycation and its role in fracture properties of bone. J Musculoskelet Neuronal Interact 2005, 5:316.
• Schwartz AV, Garnero P, Hillier TA, et al.: Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:2380–2386. This study shows association between levels of circulating AGEs and increased fracture risk in T2DM patients.
Deeg MA, Tan MH: Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res 2008, 2008:520465.
Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427–2443.
Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.
Wadman M: Avandia outcome may signal change in epidemiologists’ sway. Nat Med 2010, 16:614.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180–1188.
Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004, 351:1106–1118.
Schwartz AV, Sellmeyer DE, Vittinghoff E, et al.: Thiazolidinedione (TZD) use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006, 91:3349–3354.
Kanazawa I, Yamaguchi T, Yano S, et al.: Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int 2010 Feb 4 [Epub ahead of print].
Glintborg D, Andersen M, Hagen C, et al.: Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008, 93:1696–1701.
Grey A, Bolland M, Gamble G, et al.: The peroxisome-proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007, 92:1305–1310.
Gruntmanis U, Fordan S, Ghayee HK, et al.: The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int 2010, 86:343–349.
• Kahn SE, Zinman B, Lachin JM, et al.: Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845–851. This article provides a retrospective analysis of fracture risk and type of fractures among the ADOPT participants receiving rosiglitazone.
Zinman B, Haffner SM, Herman WH, et al.: Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010, 95:134–142.
• Loke YK, Singh S, Furberg CD: Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009, 180:32–39. This article provides a comprehensive review of available clinical trials in respect to the effect of TZDs on risk of fractures.
Jones SG, Momin SR, Good MW, et al.: Distal upper and lower limb fractures associated with thiazolidinedione use. Am J Manag Care 2009, 15:491–496.
Habib ZA, Havstad SL, Wells K, et al.: Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95:592–600.
Dormuth CR, Carney G, Carleton B, et al.: Thiazolidinediones and fractures in men and women. Arch Intern Med 2009, 169:1395–1402.
Meier C, Kraenzlin ME, Bodmer M, et al.: Use of thiazolidinediones and fracture risk. Arch Intern Med 2008, 168:820–825.
Solomon DH, Cadarette SM, Choudhry NK, et al.: A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 2009, 94:2792–2798.
Douglas IJ, Evans SJ, Pocock S, Smeeth L: The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009, 6:e1000154.
Gradiser M, Matovinovic M, Vrkljan M: Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly. Croat Med J 2007, 48:87–91.
Gatti D, Viapiana O, Rossini M, Silvano A: Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressive. J Bone Miner Res 2010, 25:1460–1462.
Rzonca SO, Suva LJ, Gaddy D, et al.: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401–406.
Lazarenko OP, Rzonca SO, Hogue WR, et al.: Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007, 148:2669–2680.
Sottile V, Seuwen K, Kneissel M: Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004, 75:329–337.
Huang S, Syed F, Suva LJ, Lecka-Czernik B: Estrogen deficiency augments TZD-induced bone loss and fat accumulation in bone in vivo [abstract]. J Bone Miner Res 2009, 24(Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=2e0a4c8c-af53-41a8-8155-8818183333bc. Accessed August 2010.
Modder UI, Monroe DG, Fraser DG, et al.: Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2. J Biol Chem 2009, 284:18767–18777.
Wan Y, Chong LW, Evans RM: PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007, 13:1496–1503.
Teitelbaum SL, Ross FP: Genetic regulation of osteoclast development and function. Nat Rev Genet 2003, 4:638–649.
• Shockley KR, Lazarenko OP, Czernik PJ, et al.: PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009, 106:232–246. This article provides an extensive analysis of the effect of rosiglitazone on gene expression in marrow MSCs.
• Shockley KR, Rosen CJ, Churchill GA, Lecka-Czernik B: PPARgamma2 regulates a molecular signature of marrow mesenchymal stem cells. PPAR Res 2007, 2007:81219. This article demonstrates that PPAR-γ2 plays a major role in regulation of cell "stemness."
Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B: Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004, 3:379–389.
Rosen CJ, Bouxsein ML: Mechanism of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006, 2:35–43.
Cao JJ, Wronski TJ, Iwaniec U, et al.: Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res 2005, 20:1659–1668.
Higgins LS, Depaoli AM: Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 2010, 91:267 S–272 S.
Glass CK, Saijo K: Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010, 10:365–376.
Lecka-Czernik B, Moerman EJ, Grant DF, et al.: Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002, 143:2376–2384.
Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B: Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 2006, 38:74–85.
Stafford JM, Elasy T: Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. Vasc Health Risk Manag 2007, 3:503–510.
Wong IP, Baldock PA, Herzog H: Gastrointestinal peptides and bone health. Curr Opin Endocrinol Diabetes Obes 2010, 17:44–50.
Zinman B, Gerich J, Buse JB, et al.: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224–1230.